Employers grapple with costs
Coverage shows employers and insurers are under pressure from surging demand for weight‑loss drugs, with some employers cutting or rethinking coverage because of price. (nbcnews.com) Market reporting also says manufacturers are targeting the self‑pay market and tiered pricing as a commercial response. (benzinga.com)
Employers and insurers are pulling back on weight-loss drug coverage as demand rises faster than many health plans can absorb. (nbcnews.com) NBC News reported on April 15 that some companies are dropping coverage for drugs such as Wegovy and Zepbound, even when executives say they want to offer the benefit, because the price is too high for employer plans. A 2024 survey cited by NBC News found fewer than 1 in 5 large United States companies covered those drugs for obesity. (nbcnews.com 1) (nbcnews.com 2) Drugmakers and pharmacy platforms are responding by building cash-pay lanes outside traditional insurance. GoodRx said on April 15 that eligible self-pay patients can get Wegovy HD for $399 a month, or $798 for two months and $1,197 for three months. (businesswire.com) (benzinga.com) Novo Nordisk and Eli Lilly have both added lower-priced or structured self-pay offers as the market broadens beyond employer coverage. NovoCare says new Wegovy patients can pay $199 a month for starter doses under a limited-time offer through June 30, 2026, while Lilly says some uninsured or non-covered Zepbound patients can start at $299 for a one-month prescription. (novocare.com) (zepbound.lilly.com) These drugs are part of the glucagon-like peptide-1 market, a class of medicines that helps regulate appetite and blood sugar and is now being sold through more channels than a standard pharmacy benefit. NBC News reported in January that 2026 was shaping up to bring more price changes, more ways to buy the drugs, and new pill options. (nbcnews.com) For employers, the math is blunt: a benefit that is popular with workers can become a budget problem when treatment is long term and uptake keeps climbing. NBC News said employers and insurers are struggling to keep up with the cost as demand for glucagon-like peptide-1 drugs surges. (nbcnews.com) For manufacturers, the current strategy is not only to win insurance coverage but also to capture patients who are willing to pay directly for faster or more predictable access. GoodRx said its Wegovy HD launch reflects a broader move toward self-pay models, and Lilly has already expanded retail pickup for self-pay Zepbound through Walmart pharmacies. (markets.ft.com) (investor.lilly.com) Public plans have also shown how quickly the bill can escalate. In North Carolina, NBC News reported in late 2024 that the State Health Plan ended coverage of this class for weight loss after projecting costs of more than $170 million in one year and more than $1 billion over six years. (nbcnews.com) The result is a split market: some patients still get employer coverage, some get manufacturer discounts, and others are pushed into cash-pay programs with tiered pricing. As long as demand stays high and monthly prices stay elevated, employers will keep treating these drugs as both a health benefit and a cost-control fight. (nbcnews.com) (businesswire.com)
